Navigation Links
A Phase IIa Interferon Free Combination Hepatitis C Trial of Simeprevir (TMC435) and TMC647055 Will Commence Shortly
Date:9/19/2012

esponder patients chronically infected with HCV genotype 1a.

Additional information about this study will be posted on http://www.clinicaltrials.gov

About Medivir

Medivir is an emerging research-based pharmaceutical company focused on infectious diseases. Medivir has world class expertise in polymerase and protease drug targets and drug development which has resulted in a strong infectious disease R&D portfolio. The Company's key pipeline asset is simeprevir (TMC435), a novel protease inhibitor in phase III clinical development for hepatitis C that is being developed in collaboration with Janssen Research & Development Ireland.

In June 2011, Medivir acquired the specialty pharmaceutical company BioPhausia. and today Medivir has a broad product portfolio with prescription pharmaceuticals in the Nordics.

Medivir's first product, the unique cold sore product Xerese®/Xerclear®, is launched in collaboration with GlaxoSmithKline to be sold OTC under the brand name ZoviDuo in Europe, Japan and Russia.

Medivir's IPO was in 1996 and currently the company has around 180 employees.

For more information about Medivir, please visit the Company's website: http://www.medivir.com

For more information about Medivir, please contact:

Medivir
Rein Piir, EVP Corporate Affairs & IR    
Direct: +46-8-440-6550 or:
Mobile: +46-708-537-292 

M:Communications
Europe: Mary-Jane Elliott, Amber Bielecka, Hollie Vile    
medivir@mcomgroup.com
+44(0)20-7920-2330



'/>"/>
SOURCE Medivir
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGaA
2. ESTEVE Announces the Publication of Comprehensive Phase I Data for a Novel Oral, First-in-class New Chemical Entity (NCE),E-52862, a Sigma-1 Receptor Antagonist (S1RA) Being Developed for Pain
3. Sosei Group Corporation QVA149 Phase III Study Meets Primary Endpoint in Reducing Exacerbations in COPD Patients and Filings in EU and Japan by End of Year
4. Debiopharm Announces First Patient Enrolled in Phase III Study for the Rare Disease Central Precocious Puberty
5. Northwest Bio Receives Regulatory Approval To Proceed With Its Phase III Trial In The UK
6. Clinical Phase Ia Trial on MIV-711 Complete and Phase Ib Trial Commences
7. Lightlake Therapeutics Inc. Announces Positive Final Phase II Clinical Trial Results of Binge Eating Disorder Treatment
8. Robert Kirsner, MD, PhD, To Present Results For Phase 2b 6-Month Follow-Up Trial Of Unique Investigational Cell-Based Therapy For Venous Leg Ulcers
9. BioHealth Innovation, Inc. Caps Next Phase Of Development With Move To New Headquarters And Addition Of Staff
10. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
11. Convergence Pharmaceuticals Announces Successful Completion of Phase I for CNV2197944 and Plans Phase II Studies in Neuropathic Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... CA (PRWEB) , ... September 02, 2015 , ... ... faults in manufacturing equipment, to creating professional commercial video content, to analysis of ... views of fascinating events that go by too quickly to process with the ...
(Date:9/1/2015)... N.J. , Sept. 1, 2015  ContraVir Pharmaceuticals, ... on the development and commercialization of targeted antiviral therapies, ... & Renshaw 17 th Annual Global Investment Conference ... place September 8-10, 2015 at The St. Regis Hotel ... James Sapirstein , Chief Executive Officer, ...
(Date:9/1/2015)... Poway, CA (PRWEB) , ... September 01, 2015 ... ... Equine Cervical Facet joint disease. , Equine cervical facet joint problems can ... joints gradually enlarge, and can cause impingement of nerve roots or of the ...
(Date:9/1/2015)... ... September 01, 2015 , ... Industry ... Development, Asia Pacific. In this newly-created position, Gibbs will lead iLab’s business operations ... iLab’s suite of tools. This entails not only introducing iLab to potential partners ...
Breaking Biology Technology:Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3ContraVir to Present at Rodman & Renshaw 17th Annual Global Investment Conference 2VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 2VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 3iLab Solutions Hires Gerard Gibbs, Director of Business Development, Asia Pacific 2iLab Solutions Hires Gerard Gibbs, Director of Business Development, Asia Pacific 3
... TIRAT CARMEL, Israel, December 2 InSightec Ltd. ... Focused,Ultrasound (MRgFUS) with the ExAblate(R) system has the ... tumors that have spread to,the bones (bone metastases). ... in the,November 11 online issue of Annals of ...
... December 2 NicOx S.A.,(NYSE Euronext Paris: ... agreement with,DSM for the commercial manufacture and ... pharmaceutical ingredient). Naproxcinod is NicOx, lead,investigational product ... Oxide-Donating (CINOD) class of,anti-inflammatory agents, which recently ...
... Biosciences, Inc., announced today the appointment of Ellen McDonald ... of Business Operations and Chief Business Officer, effective immediately. ... of experience in the biopharmaceutical industry, with expertise heading ... will report to David J. Mazzo, Ph.D., the Company,s ...
Cached Biology Technology:New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases 2New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases 3New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases 4NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 2NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 3NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 4Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer 2
(Date:8/6/2015)... and TELTOW, Germany , August 6, ... Conference, SensoMotoric Instruments (SMI) shows the world,s ... , based on Epson,s Moverio BT-200 see-through head ... With this new solution, unprecedented quality and efficiency is ... with context-sensitive displays. For the first time, professionals and ...
(Date:8/5/2015)... MOUNTAIN VIEW, Calif. , Aug. 5, 2015 /PRNewswire/ ... it exhibits continuous growth in applications, penetration into newer ... year after year. The global biosensors space has seen ... having exited the market so far. (Photo ... from Frost & Sullivan, Analysis of the Global ...
(Date:7/31/2015)... , Kina, 31. juli 2015 Den 10. ... afholdt af BGI fra den 22. - 25. oktober i ... Konferencen fejrer sin 10-års fødselsdag i år. Siden starten ... indflydelsesrige årlige møder på ,omik,-feltet, og er en af ... ICG-10 fokuserer på nylige gennembrud og fremskridt ...
Breaking Biology News(10 mins):SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2
... Valentine,s Day, chocolate helps celebrate the season. While overindulging ... right kinds of chocolate can actually make one feel ... Monica Bearden, authors of CHOCOLATEA HEALTHY PASSION (Prometheus Books, ... as well as its history, culture, sensory pleasures and ...
... 2008Systems biology scientists from diverse areas of research are ... data, and derive therapeutic targets from biological networks, reports ... point of much of the work is to characterize ... complex biological networks, according to an article in the ...
... Head of Geography at the University of Leicester has ... of modern radar technology for monitoring the rainforests. ... Brazil "We need advanced radar satellites for monitoring tropical ... America, the US, Canada and Europe had come together ...
Cached Biology News:Lower your blood pressure, hydrate your skin and reduce dental plaque -- with chocolate? 2Lower your blood pressure, hydrate your skin and reduce dental plaque -- with chocolate? 3University of Leicester professor adds new perspective to rainforest debate 2
... all-inclusive collection of key procedures for use ... developed by the leaders in Pichia expression ... book will guide you from choosing the ... analysis, to production of your protein of ...
Rad 51C Immunogen: His-tagged human Rad 51C, over-expressed in E. coli Storage: 4 C...
...
...
Biology Products: